The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.

Although not statistically significant, axi-cel showed a trend toward an improvement in OS, with a median OS not reached (NR) versus 35.1 months for axi-cel and SOC, respectively (HR, 0.73; 95% CI, 0.53–1.01; p = 0.054), and 2-year OS was 61% for axi-cel versus 52% for SOC, with longer follow-up time needed.

also in 53,322 other papers

In that case, stratification based on factors may be significant.

also in 13,097 other papers